Please note: The information displayed on this page might be outdated.
Sapience Therapeutics: Sapience Therapeutics is focused on discovering and developing peptide-based therapeutics to previously "undruggable" targets for major unmet medical needs, particularly high mortality cancers. Our drug candidates target protein-protein interactions (PPIs) that are responsible for either making the cells cancerous or dampening the immune response against tumors. These targets are considered undruggable because they are PPIs that reside inside of the cell, making them difficult to treat with small molecule drugs such as chemotherapies (which are incapable of disrupting PPIs) or biologic-based drugs such as monoclonal antibodies (which are too big to enter the cell). We aim to combine the best features of these two drug classes by developing peptides that can enter cells and disrupt these PPIs.
US - Middle Atlantic
Phase l or ll
Company Participants at Spring Private Company Showcase
Sapience Therapeutics, President/CEO/Founder
Barry Kappel is the founder, President, Chief Executive Officer and Director of Sapience Therapeutics. As a biotechnology entrepreneur, executive and native New Yorker, Dr. Kappel is driven to help develop and foster the biotechnology community in New York, and Sapience is the latest example of this effort. Prior to founding Sapience, Dr. Kappel was a senior executive of ContraFect Corporation, a company that he played an integral part in founding in 2009. As the Senior Vice President of Business Development, he was involved in all aspects of the company, including financing activities, licensing of the company's key technologies, establishing scientific collaborations with academic and corporate partners, presenting to regulatory authorities and developing a corporate strategy. Prior to ContraFect, Dr. Kappel was a Senior Consultant at Easton Associates, LLC, a boutique life science consulting firm located in Manhattan. Easton Associates has since been acquired by Navigant Consulting. Dr. Kappel holds a B.A. in Chemistry from Emory University, a Ph.D. in Immunology and Pharmacology from the Weill Cornell Graduate School of Medical Sciences and Memorial Sloan-Kettering Cancer Center, and an M.B.A. from the S.C. Johnson Graduate School of Management at Cornell University. Dr. Kappel was also chosen as a Howard Hughes Pre-Doctoral Fellow and has published 17 articles in peer-reviewed scientific journals.